ARMR Launches up to $30M Capital Raise to Advance Biodefense Platform Against Fentanyl and AI-Driven Synthetic Drug Threats
ARMR Sciences Inc. has launched a capital raise of up to $30 million, expandable to $50 million, through a private placement of Series A-1, 7% Convertible Preferred Stock. The company is developing biodefense solutions against fentanyl and synthetic drug threats, with plans for a public offering and Nasdaq listing in late 2025 or early 2026.
The company's flagship product, ARMR-100, is an immunotherapy developed at the University of Houston that showed promising results in animal studies, preventing 92% of fentanyl from entering the brain and achieving 100% blockage of the drug's effects. The technology demonstrated no cross-reactivity with common pain medications. ARMR plans to begin human trials in partnership with the Center for Human Drug Research (CHDR).
Additionally, ARMR is establishing ARMR Defense Labs to develop an AI-powered drug discovery platform for creating countermeasures against emerging synthetic threats.
ARMR Sciences Inc. ha avviato una raccolta fondi fino a 30 milioni di dollari, estendibile a 50 milioni di dollari, attraverso un collocamento privato di azioni privilegiate convertibili Serie A-1 al 7%. L'azienda sta sviluppando soluzioni di biodefesa contro le minacce di fentanyl e droghe sintetiche, con l'obiettivo di una quotazione pubblica e l'ingresso al Nasdaq tra la fine del 2025 e l'inizio del 2026.
Il prodotto di punta dell'azienda, ARMR-100, è un'immunoterapia sviluppata presso l'Università di Houston che ha mostrato risultati promettenti negli studi su animali, impedendo che il 92% del fentanyl raggiungesse il cervello e ottenendo un blocco completo degli effetti della droga. La tecnologia non ha mostrato reattività incrociata con comuni farmaci antidolorifici. ARMR prevede di avviare studi clinici sull'uomo in collaborazione con il Center for Human Drug Research (CHDR).
Inoltre, ARMR sta creando ARMR Defense Labs per sviluppare una piattaforma di scoperta di farmaci basata sull'intelligenza artificiale, destinata a creare contromisure contro le nuove minacce sintetiche.
ARMR Sciences Inc. ha iniciado una recaudación de capital de hasta 30 millones de dólares, ampliable a 50 millones de dólares, mediante una colocación privada de acciones preferentes convertibles Serie A-1 al 7%. La compañía está desarrollando soluciones de biodefensa contra las amenazas del fentanilo y drogas sintéticas, con planes para una oferta pública y cotización en Nasdaq a finales de 2025 o principios de 2026.
El producto principal de la empresa, ARMR-100, es una inmunoterapia desarrollada en la Universidad de Houston que mostró resultados prometedores en estudios con animales, previniendo que el 92% del fentanilo llegara al cerebro y logrando un bloqueo total de los efectos de la droga. La tecnología no mostró reactividad cruzada con medicamentos comunes para el dolor. ARMR planea comenzar ensayos en humanos en colaboración con el Center for Human Drug Research (CHDR).
Además, ARMR está estableciendo ARMR Defense Labs para desarrollar una plataforma de descubrimiento de fármacos impulsada por IA para crear contramedidas contra las amenazas sintéticas emergentes.
ARMR Sciences Inc.는 최대 3,000만 달러(확장 시 5,000만 달러) 규모의 자본 조달을 위해 7% 전환 우선주 시리즈 A-1의 사모 발행을 시작했습니다. 이 회사는 펜타닐 및 합성 약물 위협에 대응하는 생물 방어 솔루션을 개발 중이며, 2025년 말 또는 2026년 초에 공개 상장 및 나스닥 상장을 계획하고 있습니다.
회사의 주력 제품인 ARMR-100은 휴스턴 대학교에서 개발된 면역치료제로, 동물 실험에서 펜타닐의 92%가 뇌로 들어가는 것을 막고 약물 효과를 100% 차단하는 유망한 결과를 보였습니다. 이 기술은 일반 진통제와의 교차 반응성이 없음을 입증했습니다. ARMR은 인간 임상시험을 위해 Center for Human Drug Research (CHDR)와 협력할 계획입니다.
또한, ARMR은 신흥 합성 위협에 대응하기 위한 AI 기반 신약 개발 플랫폼을 구축하기 위해 ARMR Defense Labs를 설립하고 있습니다.
ARMR Sciences Inc. a lancé une levée de fonds pouvant atteindre 30 millions de dollars, extensible à 50 millions de dollars, via un placement privé d'actions privilégiées convertibles de Série A-1 à 7%. La société développe des solutions de biodéfense contre les menaces liées au fentanyl et aux drogues synthétiques, avec des projets d’introduction en bourse et de cotation au Nasdaq fin 2025 ou début 2026.
Le produit phare de l'entreprise, ARMR-100, est une immunothérapie développée à l'Université de Houston qui a montré des résultats prometteurs lors d'études animales, empêchant que 92 % du fentanyl n'atteigne le cerveau et réalisant un blocage total des effets de la drogue. La technologie n'a montré aucune réactivité croisée avec les médicaments antidouleur courants. ARMR prévoit de débuter des essais cliniques humains en partenariat avec le Center for Human Drug Research (CHDR).
De plus, ARMR crée ARMR Defense Labs pour développer une plateforme de découverte de médicaments alimentée par l'intelligence artificielle, destinée à concevoir des contre-mesures contre les menaces synthétiques émergentes.
ARMR Sciences Inc. hat eine Kapitalerhöhung von bis zu 30 Millionen US-Dollar, erweiterbar auf 50 Millionen US-Dollar, durch eine Privatplatzierung von Serie A-1, 7% wandelbaren Vorzugsaktien gestartet. Das Unternehmen entwickelt Biodefenselösungen gegen Fentanyl- und synthetische Drogenbedrohungen und plant einen Börsengang sowie eine Notierung an der Nasdaq Ende 2025 oder Anfang 2026.
Das Flaggschiffprodukt des Unternehmens, ARMR-100, ist eine Immuntherapie, die an der University of Houston entwickelt wurde und in Tierversuchen vielversprechende Ergebnisse zeigte: Sie verhinderte, dass 92 % des Fentanyls ins Gehirn gelangten, und erreichte eine 100%ige Blockade der Wirkungen der Droge. Die Technologie zeigte keine Kreuzreaktivität mit gängigen Schmerzmitteln. ARMR plant, in Zusammenarbeit mit dem Center for Human Drug Research (CHDR) mit Humanstudien zu beginnen.
Zusätzlich gründet ARMR die ARMR Defense Labs, um eine KI-gestützte Wirkstoffentdeckungsplattform zu entwickeln, die Gegenmaßnahmen gegen aufkommende synthetische Bedrohungen schafft.
- Promising animal study results showing 92% prevention of fentanyl entering the brain
- Planned expansion to $50 million maximum offering size
- Partnership with established research center CHDR for human trials
- No cross-reactivity with common pain medications in initial studies
- Development of AI-powered drug discovery platform for future threats
- Experienced leadership team including DoD veterans and MIT graduates
- Product still in early stages with no human trial data yet
- Significant capital needed for development and trials
- Regulatory approval uncertainties and timeline risks
- Competitive market with established pharmaceutical and defense contractors
Insights
ARMR's $30-50M raise positions it to advance fentanyl immunotherapy toward human trials after promising animal results showing 92% prevention efficacy.
ARMR Sciences is launching a
The company's flagship product, ARMR-100, represents a paradigm shift in overdose prevention. Unlike current reactive approaches that treat overdoses after they occur, this immunotherapy aims to provide preventative protection by training the immune system to neutralize fentanyl in the bloodstream before it reaches the brain. Animal studies conducted over six years demonstrated impressive results: the formulation prevented approximately
Critical for clinical viability, ARMR-100 demonstrated no cross-reactivity with common pain and addiction medications like morphine and oxycodone, suggesting these therapies would remain effective when needed. The company is now preparing to translate these animal results to humans through clinical trials led by former DoD physician Dr. Shon Remich in partnership with the Center for Human Drug Research.
Beyond ARMR-100, the company plans to develop an AI-powered drug discovery platform (ARMR Defense Labs) to create countermeasures against emerging synthetic threats. This positions ARMR within the growing defense tech sector, potentially capitalizing on significant U.S. defense spending and increased government focus on the fentanyl crisis.
For investors considering the private placement, the minimum investment is
- ARMR is developing pre-exposure biodefense solutions to protect American lives from fentanyl and synthetic drug threats weaponized by
U.S. adversaries. - Up to
$30 million - The company's lead product is an immunotherapy intended to provide preventative annual protection against illicit fentanyl.
The current private offering consists of shares of the Company's Series A-1,
The battlefield is evolving. Wars are no longer fought with bullets and bombs; they are now waged with unmanned drones, cyberwarfare, and covert chemical weapons such as fentanyl. Unfortunately, advancements in AI drug discovery may enable America's enemies to swiftly design more potent and lethal synthetic drugs. These chemical threats are being rapidly deployed as chemical weapons.
In this rapidly changing landscape, fentanyl represents the top synthetic drug threat. Its deadly rise is no accident. It's the result of a perfect storm: an optimized substance that's cheap to manufacture, covertly cut into counterfeit pills and recreational drugs, and quietly distributed through social media. The impact has been catastrophic. According to the DEA and CDC, fentanyl is now the leading cause of death for Americans aged 18 to 45, with overdose claiming 220 lives every single day.
In response, ARMR plans to equip Americans with innovative biodefense countermeasures to protect against both current and emerging synthetic drug threats. Its flagship technology, ARMR-100, is an immunotherapy originally developed at the University of
ARMR's next step is to translate the promising animal data into humans. ARMR's Chief Medical Officer, Dr. Shon Remich, a former leader of the Department of Defense's (DoD) PEPFAR program and 23-year
"Our development strategy is to build solutions that are battlefield-ready for the military and first responders, while engineering to eventually offer solutions for broader civilian use. If they choose it, the American public deserves access to the same level of protection as our soldiers," said ARMR Chief Medical Officer Dr. Shon Remich.
If successful, the formulation could mark a shift in overdose prevention, a switch from last-second rescue to pre-exposure defense. Unlike existing treatments that act only after tragedy strikes, ARMR-100 is being designed to prevent that tragedy from occurring. Specifically, it's in development to train the body's immune system to neutralize fentanyl in the bloodstream before it can reach the brain, blocking both the respiratory failure, which causes death, and the euphoric high, which can lead to addiction.
The company says ARMR-100 is only the beginning, with plans to develop a drug discovery platform powered by artificial intelligence, enabling more efficient and effective development of countermeasures against current and emerging synthetic threats. This division, called ARMR Defense Labs, is being established to facilitate safe, efficient, and scalable countermeasures.
"We believe fentanyl is just the beginning. As AI accelerates the creation of novel synthetic compounds, we must innovate to stay ahead of the curve," said Collin Gage, Co-Founder & CEO of ARMR Sciences. "I'm confident the fortified team of veterans, scientists, and mission-driven experts will be the right one to lead the next generation of biodefense. We have the opportunity to build upon foundational research made possible by support from the
ARMR plans to develop its immunotherapies as a central part of the larger defense tech movement. According to recently released figures from the Stockholm International Peace Research Institute (SIPRI),
"We believe ending the fentanyl crisis is America's most critical modern mission," said Gage. "We're not here to patch broken systems; we're working on an entirely new treatment approach. We want to provide improved tools for Americans to defend themselves against synthetic drug threats."
Accredited investors will have the opportunity to invest in this private offering.
The private offering is solely available to accredited investors* and consists of shares of the Company's Series A-1,
Full offering details and the ability to sign up to learn more about our contemplated public offering can be found at investARMR.com.
For specific questions related to the offering or accreditation status, email us at: ir@armrsciences.com, or visit https://investARMR.com/.
*Please note: Accredited investors are defined under Rule 501(a)(1) of Regulation D promulgated by the Securities and Exchange Commission under the Securities Act, as amended (the "Securities Act').
The Shares offered in the private offering will not be and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in
The definition of an individual accredited investor under the Securities Act of 1933, Rule 501(a)[1] is that you have (i) gross individual income of
About ARMR Sciences Inc.
ARMR Sciences Inc. is America's biodefense technology company, developing next-generation countermeasures against synthetic drug threats, such as fentanyl. Through its foundational license, ARMR is backed by early-stage research funding from the
About Digital Offering, LLC
Digital Offering, LLC ("DO"), a leader in crowd financed public offerings, is a next-generation investment bank with a focus on technology and innovation, utilizing The Jumpstart Our Business Startups Act, or JOBS Act.
For over a decade they specialize in helping high-quality private and public growth companies access
ARMR Sciences is currently undertaking a private placement offering pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Rule 506(c) of Regulation D promulgated thereunder. Investors should consider the investment objectives, risks, and investment time horizon of the Company carefully before investing. The private placement memorandum relating to this offering of equity interests by the Company will contain this and other information concerning the Company and the securities referenced in this document, including risk factors, which should be read carefully before investing. You should be aware that (i) the securities may be sold only to "accredited investors," as defined in Rule 501 of Regulation D; (ii) the securities will only be offered in reliance on an exemption from the registration requirements of the Securities Act and will not be required to comply with specific disclosure requirements that apply to registration under the Securities Act; (iii) the United States Securities and Exchange Commission will not pass upon the merits of or give its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials; (iv) the securities will be subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities; investing in these securities involves a high degree of risk, and investors should be able to bear the loss of their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time.
The offering documents may include "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward looking statements. This information is supplied from sources we believe to be reliable but we cannot guarantee accuracy. Although we believe our expectations expressed in such forward-looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to the risks and uncertainties set forth in the attached materials, which could cause actual results to differ materially from the anticipated results set forth in such forward-looking statements. Any forward-looking statement made by us speaks only as of the date on which it is made, and we undertake no obligation to publicly update any forward-looking statement except as may be required by law.
The Company is "Testing the Waters" under Regulation A under the Securities Act of 1933. The Company is not under any obligation to make an offering under Regulation A. No money or other consideration is being solicited in connection with the information provided, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until an offering statement on Form 1-A has been filed and until the offering statement is qualified pursuant to Regulation A of the Securities Act of 1933, as amended, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. Any person's indication of interest involves no obligation or commitment of any kind. The information in that offering statement will be more complete than the information the Company is providing now, and could differ materially. You must read the documents filed. No offer to sell the securities or solicitation of an offer to buy the securities is being made in any state where such offer or sale is not permitted under the "blue sky" or securities laws thereof. No offering is being made to individual investors in any state unless and until the offering has been registered in that state or an exemption from registration exists therein. The securities offered using Regulation A are highly speculative and involve significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards.
Contact:
For questions to ARMR Sciences:
contact@armrsciences.com
For investment questions:
ir@armrsciences.com
[1] There can be no guarantee that ARMR Sciences Inc. will complete a public offering or be approved to publicly list on Nasdaq or any stock exchange.
View original content to download multimedia:https://www.prnewswire.com/news-releases/armr-launches-up-to-30m-capital-raise-to-advance-biodefense-platform-against-fentanyl-and-ai-driven-synthetic-drug-threats-302521254.html
SOURCE ARMR Sciences Inc.
FAQ
What is ARMR's planned capital raise amount and structure?
What are the key results from ARMR-100's animal studies?
When does ARMR plan to go public?
How does ARMR-100 differ from existing fentanyl treatments?
What is ARMR's strategy for future drug threats?
